Week Phase News Today

$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over...

Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks Anavex plans to proceed to... | March 30, 2023

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation...

/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...

/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...

Additional data showed numerical improvement in activities of daily living , a protocoled secondary endpoint and a functional measure of independence Plasma biomarker data in a pre-specified... | August 3, 2022

New data on ruxolitinib cream (Opzelura) in vitiligo and atopic dermatitis will be presented, including 52-week results from the Phase 3 TRuE-V vitiligo program which will be featured as a late-breaking

18.03.2022 - Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology (AAD) Annual Meeting, held March 25-29, 2022, in Boston. New 52-week data ... Seite 1

- LYBALVI Demonstrated Less Weight Gain Compared to Olanzapine in Patients With Schizophrenia, Schizophreniform Disorder or Bipolar I Disorder - DUBLIN, Feb. 8, 2022 /PRNewswire/ -- Alkermes